Clinical trials: Cerebral Stroke
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention…
- Trial name
- NCT05321810
- Testing
- Apixaban, Warfarin
- Where
- Japan
- Volunteers
- 193,565 people
- Sponsor
- Pfizer
Acute Ischemic Stroke
Feasibility Study of RapidPulseTM Aspiration System as Frontline Approach for Stroke Patients
A Feasibility Study to evaluate the initial safety and performance of the RapidPulseTM Aspiration System in the treatment of patients with Acute Ischemic Stroke (AIS) due to Large Vessel Occlusion (LVO).
- Trial name
- RapidPulseFS (NCT05122637)
- Testing
- RapidPulseTM Aspiration System, Standard of Care Aspiration Thrombectomy System
- Where
- 5 sites in Brazil, Denmark and 3 more
- Volunteers
- 80 people
- Sponsor
- RapidPulse, Inc
Left Atrial Appendage Exclusion
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.
- Trial name
- EXCLUDE (NCT00779857)
- Testing
- AtriCure LAA Exclusion System
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- AtriCure, Inc.
Cerebrovascular Accident
Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients
The purpose of this study is to assess the safety and feasibility of the NeuroFlo™ catheter in treating patients with ischemic stroke whose last time symptom-free was between 8-24 hours prior to treatment.
- Trial name
- Flo 24 (NCT00436592)
- Testing
- NeuroFlo™ Catheter
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- CoAxia
Post-stroke Upper Limb Spasticity
Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity
Multicenter, randomized, double-blind, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Subjects with Post-stroke Upper Limb Spasticity
- Trial name
- NCT05382767
- Testing
- CKDB-501A, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- CKD Bio Corporation
Mild Cognitive Impairment, Ischemic Stroke
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
The purpose of this study is: to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke to evaluate safety of MMH-MAP in the treatment of mild…
- Trial name
- NCT03815292
- Testing
- MMH-MAP
- Where
- 28 sites in Russia
- Volunteers
- 276 people
- Sponsor
- Materia Medica Holding
Atrial Fibrillation, Stroke
Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder
This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).
- Trial name
- NCT01920412
- Testing
- LAmbre Left Atrial Appendage(LAA) Occluder
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Foot Drop, Stroke
Ankle Robotics After Stroke
The randomized study (in Phase II of the U44) compares the efficacy and durability of 9 weeks (18 sessions) of robot-assisted physical therapy (PTR) versus physical therapy (PT) alone on foot drop as assessed by gait biomechanics…
- Conditions
- Foot Drop, Stroke, Hemiparesis
- Trial name
- NCT04594837
- Testing
- PTR Physical Therapy while wearing Robot group (Phase II), Physical Therapy Only (Phase II), Cross over group for Physical Therapy n Sub-Acute group. (Phase II)
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- NextStep Robotics Inc.
Acute Coronary Syndrome
Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina
The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.
- Trial name
- NCT00353067
- Testing
- veliflapon (DG-031)
- Where
- 11 sites in United States
- Volunteers
- 3,450 people
- Sponsor
- deCODE genetics
Stroke, Ischemic Stroke
Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes
Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours…
- Conditions
- Stroke, Ischemic Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT Reg (NCT07335185)
- Testing
- Supernova revascularization device
- Volunteers
- 3,000 people
- Sponsor
- Gravity Medical Technology, INC
Cerebral Infarction
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
The study is designed to assess safety of Vorapaxar when added to standard of care (aspirin) in Japanese subjects with cerebral infarction.
- Trial name
- NCT00684515
- Testing
- Vorapaxar 2.5 mg, Vorapaxar 1 mg, Aspirin 75-150 mg
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Ischemic Stroke
DNS-3379 vs. Placebo in Stroke Rehabilitation
This is a randomized, double-blind, placebo-controlled parallel group outpatient 42-day treatment study that will utilize standard stroke rehabilitation outcome measures to evaluate the effect of DNS-3379 on upper extremity motor…
- Trial name
- SPIRIT (NCT03254160)
- Testing
- DNS-3379
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 1 people
- Sponsor
- Dart NeuroScience, LLC
Ischemic Stroke, Neovascularization
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24…
- Trial name
- DISTALS (NCT05152524)
- Testing
- Tigertriever 13
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 149 people
- Sponsor
- Rapid Medical
Atrial Fibrillation, Bleeding
HEAL-LAA Clinical Trial
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
- Conditions
- Atrial Fibrillation, Bleeding, Stroke
- Trial name
- HEAL-LAA (NCT05809596)
- Testing
- WATCHMAN FLX Pro LAAC Device
- Where
- 45 sites in United States
- Volunteers
- 949 people
- Sponsor
- Boston Scientific Corporation
Acute Ischemic Stroke
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to…
- Trial name
- NCT06129175
- Testing
- Neuroncell-EX
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Cytopeutics Sdn. Bhd.
Acute Ischemic Stroke
Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke
The purpose of this study is to identify a safe and effective bolus dose of intra-arterial/intra-thrombus alfimeprase in acute ischemic stroke (AIS) 3 to 9 hours from symptom onset.
- Trial name
- NCT00499902
- Testing
- alfimeprase
- Where
- 22 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- ARCA Biopharma, Inc.
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01468701
- Where
- 666 sites in United States, Argentina and 19 more
- Volunteers
- 37,235 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke
This is a 3-arm, prospective, randomized, double-blind, and controlled clinical study, with 3 months of treatment to evaluate efficacy of DLBS1033 in bleeding profile and clinical outcome in patients with acute ischemic stroke…
- Trial name
- NCT01790997
- Testing
- DLBS1033, Aspirin, Clopidogrel
- Where
- Indonesia
- Volunteers
- 126 people
- Sponsor
- Dexa Medica Group
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC
Cerebrovascular Accident
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs.
- Trial name
- NCT00311402
- Testing
- Aggrenox capsule, Acetylsalicylic Acid (ASA)
- Where
- 151 sites in Japan
- Volunteers
- 1,295 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.